Memantine Grindeks (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist of the NMDA receptor. By blocking the receptor’s ion channel, it limits excessive calcium influx caused by overstimulation of glutamate, thereby reducing neuronal injury while preserving normal synaptic signaling.

The dosing regimen for Memantine Grindeks is determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Memantine Grindeks, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas cholinesterase inhibitors (e.g., donepezil) increase acetylcholine levels. Memantine is typically used in moderate to severe disease and may be combined with a cholinesterase inhibitor for additive benefit, while the latter are often first‑line for mild disease.

Memantine Grindeks should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

Memantine Grindeks is taken orally, usually once daily after a meal to improve tolerability. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious adverse events, though rare, include seizures, severe allergic reactions such as anaphylaxis, cardiac arrhythmias, hallucinations or psychosis, and liver function abnormalities. Patients should seek immediate medical attention if any of these symptoms occur.

Memantine Grindeks is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA‑receptor antagonists.